Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01131312 · ClinicalTrials.gov registry record · Phase 3
Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 5,060
- Enrollment target
NCT01131312: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT01131312 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 5,060 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01131312, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,060 participants
- Enrollment target
Study Summary
Approximately 65 million Pap smears are performed each year in the United States. The vast majority of results are negative (no abnormality identified) but about 5 percent to 8 percent are reported as abnormal. Most low-grade changes regress spontaneously; only a minority of such lesions would progress to a cancer precursor without treatment. However, there is no way to determine morphologically which patients are at risk or progression. Therefore, both high- and low-grade lesions were often managed with colposcopy and directed biopsy. Epidemiologic, virologic and molecular studies have clearly demonstrated that human papillomavirus (HPV) is the central cause of cervical cancer. The motivation for the Atypical squamous cells of undetermined significance (ASCUS)- Low grade squamous intraepithelial lesion (LSIL) Triage Study (ALTS) trial was to use the information we have gained about the role of HPV to design better treatment and prevention strategies to reduce the burden of cervical cancer and its precursors. ALTS consisted of three management strategies: (1) immediate colposcopy of all women; (2) repeat cytology with colposcopy only if the results show a high grade lesion; and (3) HPV testing and repeat cytology in combination, with referral to colposcopy if either the HPV test is positive or the cytology shows a high grade lesion. Four Clinical Centers University of Alabama, Birmingham Alabama (AL); Magee-Womens Hospital, Pittsburgh Pennsylvania (PA); University of Oklahoma, Oklahoma City OK; and University of Washington, Seattle Washington (WA) enrolled approximately 5,000 women with recent diagnosis of ASCUS or LSIL. Participants were followed at six month intervals for a total of 2 years. The ALTS database and ALTS specimens continue to be a valuable research resource in studies of cervical cancer precursors, screening tests, visual assessment of the cervix and investigation of biomarkers.
Interventions
- PROCEDURE Colposcopy
- DEVICE Thinprep
- DEVICE Hybrid capture 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,060 participants |
| Start Date | 2008-02-20 |
| Est. Completion | 2009-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01131312
The ClinicalTrials.gov registry entry for NCT01131312 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,060 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Colposcopy is the first listed.
NCT01131312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01131312 about?
NCT01131312 is a clinical study titled "Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)". Approximately 65 million Pap smears are performed each year in the United States. The vast majority of results are negative (no abnormality identified) but about 5 percent to 8 percent are reported as abnormal. Most low-grade changes regress spontaneously; only a minority of such lesions would progr...
What is the current status of trial NCT01131312?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,060 participants. The study started on 2008-02-20. Estimated completion is 2009-02-05.
What interventions are being tested in trial NCT01131312?
The interventions under investigation include: Colposcopy (PROCEDURE), Thinprep (DEVICE), Hybrid capture 2 (DEVICE).
Who is sponsoring clinical trial NCT01131312?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.